secwatch / observer
8-K filed May 21, 2026, 4:01 PM ET ticker PHAT CIK 0001783183
other confidence high sentiment neutral materiality 0.15

Phathom stockholders elect three Class I directors, ratify EY, approve say-on-pay

Phathom Pharmaceuticals, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Phathom Pharmaceuticals, Inc. shareholders approved Approval of the Compensation of the Named Executive Officers ("say-on-pay") at the 2026-05-19 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-05-19
Exact text from the filing
Proposal No. 3 – Approval of the Compensation of the Named Executive Officers (“say-on-pay”) The Company’s stockholders voted and approved, on a non-binding, advisory basis, the compensation of the named executive officers: Votes For Votes Against Abstentions Broker Non-Votes 44,449,761 2,532,145 165,675 17,487,652
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Phathom Pharmaceuticals, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-05-19 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-05-19
Exact text from the filing
Proposal No. 2 - Ratification of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for fiscal 2026: Votes For Votes Against Abstentions 64,482,757 49,661 102,815
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Phathom Pharmaceuticals, Inc. shareholders approved Election of Class I Directors at the 2026-05-19 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-19
Exact text from the filing
Proposal No. 1 - Election of Class I Directors At the Annual Meeting, the Company’s stockholders elected the persons listed below as Class I directors for a three-year term expiring at the Company’s 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Directors Votes For Withheld Broker Non-Votes Steven Basta 42,656,800 4,490,781 17,487,652 Theodore R. Schroeder 42,578,532 4,569,049 17,487,652 Mark Stenhouse 41,249,990 5,897,591 17,487,652
View on SEC.gov

Browse all shareholder votes →

Phathom Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-234379
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.